The Carlyle Group created Bidco to buy Vectura, which specializes in inhalers and works with major drugmakers from Novartis to GlaxoSmithKline. The company’s technology is used in 13 inhaled and 11 non-inhaled products, according to a statement on the deal.
Vectura also has a portfolio of treatments in development with partners, the companies said, although it’s been less successful in bringing its own drugs to market. Vectura shelved an asthma therapy in 2018 after it failed in a Phase 3 study.
The purchase is part of a wave of investment firms buying up contractors in the pharmaceutical business. With medicines becoming increasingly complex, biotechs and traditional pharma companies are relying more and more on specialists to develop and manufacture new therapies. READ MORE
By Kristin Jensen
Source: biopharmadive.com
UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.
argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.
